These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12616665)

  • 1. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.
    Capparelli EV; Englund JA; Connor JD; Spector SA; McKinney RE; Palumbo P; Baker CJ
    J Clin Pharmacol; 2003 Feb; 43(2):133-40. PubMed ID: 12616665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
    J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
    Gibb D; Barry M; Ormesher S; Nokes L; Seefried M; Giaquinto C; Back D
    Br J Clin Pharmacol; 1995 May; 39(5):527-30. PubMed ID: 7669489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    Zhou XJ; Sheiner LB; D'Aquila RT; Hughes MD; Hirsch MS; Fischl MA; Johnson VA; Myers M; Sommadossi JP
    Antimicrob Agents Chemother; 1999 Jan; 43(1):121-8. PubMed ID: 9869576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262).
    McCance-Katz EF; Rainey PM; Jatlow P; Friedland G
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):435-43. PubMed ID: 9715839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team.
    Raskino C; Pearson DA; Baker CJ; Lifschitz MH; O'Donnell K; Mintz M; Nozyce M; Brouwers P; McKinney RE; Jimenez E; Englund JA
    Pediatrics; 1999 Sep; 104(3):e32. PubMed ID: 10469815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of zidovudine in HIV-positive patients with liver disease.
    Bareggi SR; Cinque P; Mazzei M; D'Arminio A; Ruggieri A; Pirola R; Nicolin A; Lazzarin A
    J Clin Pharmacol; 1994 Jul; 34(7):782-6. PubMed ID: 7929874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
    J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylated zidovudine concentrations in mononuclear cells in pediatric patients with human immunodeficiency virus infections.
    Wintermeyer SM; Nahata MC; Brady MT; Sobol BJ; Venglarcik JS 3rd ; Baker RC; Hunkler JA; McOwen NM
    Pediatr AIDS HIV Infect; 1997 Apr; 8(2):120-6. PubMed ID: 11361778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children.
    Fauchet F; Treluyer JM; Frange P; Urien S; Foissac F; Bouazza N; Benaboud S; Blanche S; Hirt D
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4801-8. PubMed ID: 23877688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity.
    Stretcher BN; Pesce AJ; Frame PT; Greenberg KA; Stein DS
    AIDS; 1994 Jun; 8(6):763-9. PubMed ID: 8086134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions.
    Burger DM; Meenhorst PL; ten Napel CH; Mulder JW; Neef C; Koks CH; Bult A; Beijnen JH
    AIDS; 1994 Dec; 8(12):1683-9. PubMed ID: 7888117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum immunoreactive erythropoietin levels and associated factors amongst HIV-infected children.
    Allen UD; King SM; Gomez MP; Lapointe N; Forbes JC; Thorne A; Kirby MA; Bowker J; Raboud J; Singer J; Mukwaya G; Tobin J; Read SE
    AIDS; 1998 Oct; 12(14):1785-91. PubMed ID: 9792379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
    Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; Diaz C; Yogev R; McKinney RE; Abrams EJ; Mofenson LM
    Pediatrics; 1999 May; 103(5):e62. PubMed ID: 10224206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
    Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
    Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062).
    Moore KH; Raasch RH; Brouwer KL; Opheim K; Cheeseman SH; Eyster E; Lemon SM; van der Horst CM
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2732-7. PubMed ID: 8593010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients.
    Wintergerst U; Rolinski B; Bogner JR; Notheis G; Goebel FD; Roscher AA; Belohradsky BH
    Antimicrob Agents Chemother; 1997 May; 41(5):1143-5. PubMed ID: 9145885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.